Why Government Health Programs Pay Double for Generic Drugs

Episode 30 of The Fiscal Policy Podcast investigates a strange but costly inefficiency: government health programs in the US often pay far more for the exact same generic drugs than private insurers do. Lucas breaks down a 2025 Government Accountability Office report finding that Medicare Part D paid an average of 2.3 times more than commercial plans for 40 common generics in 2023 — costing taxpayers an extra $1.8 billion a year. He explains the structural reasons: opaque pharmacy benefit manager rebates, statutory pricing floors, and a reimbursement formula that was originally designed for brand-name drugs. Luna pushes back on the assumption that government procurement is always wasteful, noting that the VA and Department of Defense negotiate much better prices through a centralized formulary. The episode ends with a real-world reform proposal from the bipartisan Senate Generic Drug Pricing Act, introduced March 2026, which would cap Medicare Part D generic reimbursements at 150% of the national average commercial price. #GenericDrugs #MedicarePartD #GovernmentWaste #DrugPricing #PharmacyBenefitManagers #GAO #SenateGenericDrugPricingAct #FiscalPolicy #TaxpayerDollars #PublicSpending #Economics #LucasAndLuna #FexingoBusiness #BusinessPodcast #HealthEconomics #Procurement #BipartisanReform #Episode30 Keep every episode free: buymeacoffee.com/fexingo